Healthcare Professional Blog

Education Library

 

DanGer Shock Results from Dr. Jacob Møller at ACC 2024

Jacob Møller, MD, the principal investigator of the DanGer Shock trial, discusses study results he presented at ACC 2024.

Sign Up for Latest Updates

Stay up-to-date on the latest clinical data and resources.

All Posts

Filter Results

Condition

Audience

Topic

Type

TCT 2022: OPTIMUM Study Sub-Analysis Results

Adam Salisbury, MD, presents preliminary results from the OPTIMUM Study at TCT 2022.

Dr. Jonathan Hill: Influential Trials in High-risk PCI at TCT 2022

At TCT 2022, Jonathan Hill, MD, presents the influential high-risk PCI trials shaping the future of ischemic heart failure therapy.

81% Survival at 30 Days in a Multi-Center, Multi-Society Study of  of AMICS Patients Supported With Impella® Heart Pumps in Japan

Junya Ako, MD, presents outcomes in AMI cardiogenic shock from Japan’s J-PVAD study at TCT 2022.

TCT 2022: Data Integrity in Real-World Evidence

Robert Yeh, MD, discusses how we analyze data, make treatment decisions and participate in developing clinical evidence.

Case Study Epitomizing Results from RESTORE EF  

Aditya Bharadwaj, MD, an investigator for the RESTORE EF study, presents a case study epitomizing the results from the trial.

RESTORE EF: Ejection Fraction Improvement with Complete Revascularization

Mitul Patel, MD, discusses the RESTORE EF study and a successful case of improved ejection fraction with complete revascularization.

RESTORE EF Case Study: Contemporary Practices for Impella®-Supported Complete Revascularization

Jason Wollmuth, MD, describes best practice techniques for Impella-supported complete revascularization in a RESTORE EF case.

Building Collaboration Between Interventionalists and Cardiac Surgeons

Arman Kilic, MD, discusses his experiences with collaboration between interventional cardiology and cardiac surgery, particularly regarding Impella 5.5® with SmartAssist® and ECpella™.

STEMI-DTU RCT and the Radical, Disruptive Concept of Delayed Reperfusion

Navin Kapur, MD, discusses the latest science underlying reperfusion and unloading and how it led to the STEMI-DTU pilot and pivotal trials.

IABP for Acute-On-Chronic Heart Failure Complicated by Cardiogenic Shock

Federico Pappalardo, MD, describes the role of IABP in the treatment of acute-on-chronic heart failure complicated by cardiogenic shock. 

ECpella versus ECMO in Cardiogenic Shock: Two Independent Meta-analyses

Mario Iannaccone, MD and Vasileios Panoulas, MD, discuss two meta-analyses demonstrating improved survival in cardiogenic shock managed with ECMO and Impella (ECpella™) versus ECMO alone.

Rollout of the PROTECT IV Trial at Dresden Heart Center

Charles Simonton, MD, interviews Prof. Norman Mangner, MD, from Dresden Heart Center, about the rollout of the PROTECT IV trial. The interview focuses on an update on the PROTECT IV trial in light of the upcoming Investigator Meeting at the EuroPCR in Paris in May 2022.

STEMI DTU Rollout at the Heart and Vascular Center Essen

The focus of the interview between Charles Simonton, MD, and PD Fadi Al-Rashid, MD, is an update on the STEMI DTU trial in light of the investigator meeting at EuroPCR in Paris in May 2022.

Interview Dr. Mario Iannaccone: Comparison of ECMO vs ECpella in patients with non post-pericardiotomy cardiogenic shock: An updated meta-analysis

Dr. Mario Iannaccone is interviewed on "Comparison of ECMO vs ECpella in patients with non post-pericardiotomy cardiogenic shock: An updated meta-analysis".

Interview Dr. Mario Iannaccone: Short term outcomes of Impella® circulatory support for high-risk percutaneous coronary intervention a systematic review and meta-analysis

Dr. Mario Iannaccone is interviewed on "Short term outcomes of Impella® circulatory support for high-risk percutaneous coronary intervention a systematic review and meta-analysis".

Subscribe for Our Healthcare Professional Newsletter

Subscribe for Our Healthcare Professional Newsletter

By subscribing you will receive our HeartRecovery newsletter for healthcare professionals with latest Impella® device news about recordings, interviews, upcoming and past events or clinical evidence.

CAMP PCI™

A Community Created by Physicians for Physicians

CAMP PCI was developed by physicians for physicians in an effort to respond to a growing crisis in coronary artery disease and heart failure.

Downloads

Discover further resources like brochures, data sheets and indications for use.

NPS-891

This information is intended for use by customers, patients, and healthcare professionals in [region] only. We recognize that the Internet is a global communications medium; however, laws, regulatory requirements, and product information for medical products can vary from country to country. The product information included here may not be appropriate for use outside [region], and the information from other sites you visit may not be appropriate for use in [region].